FeesSafety
Pluang+

SRX Global updates on engineered T-cell therapy progress amid Pfizer's $330M CAR-T deal with Starna.

Market News
20 Nov 2026, 19:58 WIB
GlobeNewsWire
View Source
Bullish
SRX Global updates on engineered T-cell therapy progress amid Pfizer's $330M CAR-T deal with Starna.

SRX Global highlighted Pfizer's $330 million upfront deal with Starna for CAR-T therapies, signaling strong pharma interest in engineered T-cell platforms. SRX is acquiring CERo Therapeutics, which develops a distinct engineered T-cell therapy, CER-1236, currently in Phase 1/1b trials for blood cancers. The update underscores SRX's confidence in the field's long-term potential as CERo advances clinical development. The Pfizer-Starna deal and CERo's ongoing trial progress reflect growing momentum in engineered T-cell therapies for autoimmune diseases and cancer.

SRX Global's update on engineered T-cell strategy provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 21, 2026 01:11 WIB: out of 150 priced health-sector US stocks, 56 rose and 93 fell. Notable movers include BFLY at USD 5.46 with a -6.67% change and a typical hold time of 19 days, ALMS at USD 4.05 down 6.47% with a 22-day hold, and RXRX at USD 2.55 down 6.25%, with Pluang order activity showing 68% sell and 32% buy, and a typical hold time of 23 days.

More News

Vesta raises 2026 revenue growth forecast to 12.5% amid strong industrial leasing in Mexico.

Vesta raises 2026 revenue growth forecast to 12.5% amid strong industrial leasing in Mexico.

Corporación Inmobiliaria Vesta increased its full-year 2026 revenue growth guidance to between 11.5% and 12.5%, driven by rising tenant occupancy and an expanding industrial real estate portfolio in Mexico. The company is benefiting from shifts towar...

Company Fundamentals
Bullish
53 minutes ago
Cementos Pacasmayo Q3 EBITDA rises 45% on cost cuts and energy deals, with 4% volume growth forecast.

Cementos Pacasmayo Q3 EBITDA rises 45% on cost cuts and energy deals, with 4% volume growth forecast.

Cementos Pacasmayo reported a 45% year-over-year increase in Q3 EBITDA to 233.1 million Peruvian soles, driven by cost efficiencies and a new long-term energy contract that lowered electricity expenses. Cement segment revenues grew 21.3% to 571.6 mil...

Company Fundamentals
Bullish
53 minutes ago
Intuitive Machines outshines Rocket Lab in 2027 space race with strong growth and better valuation.

Intuitive Machines outshines Rocket Lab in 2027 space race with strong growth and better valuation.

Intuitive Machines and Rocket Lab are key players in the growing commercial space industry, focusing on lunar infrastructure and satellite launch services respectively. Intuitive Machines shows rapid revenue growth and a strong order backlog, despite...

Market News
Neutral
53 minutes ago
O-I Glass reports Q3 earnings drop due to high energy costs in Europe, offsets with Americas growth and cost cuts.

O-I Glass reports Q3 earnings drop due to high energy costs in Europe, offsets with Americas growth and cost cuts.

O-I Glass saw a sharp earnings decline in Q3 2026 driven by soaring energy costs and operational challenges in Europe, while the Americas segment grew sales by over 3% aided by the Fit-to-Win cost reduction program. The company is restructuring Europ...

Company Fundamentals
Neutral
53 minutes ago
OXXO Mexico sales rise 9.2% with new store openings and digital growth in Q2 2026

OXXO Mexico sales rise 9.2% with new store openings and digital growth in Q2 2026

In Q2 2026, OXXO Mexico saw a 9.2% increase in same-store sales driven by a 3.5% rise in customer traffic, reversing previous declines through customer-focused pricing and product strategies. The digital platform Spin by OXXO grew its active users by...

Company Fundamentals
Bullish
53 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App